Logo image of SRPT

SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

NASDAQ:SRPT - Nasdaq - US8036071004 - Common Stock - Currency: USD

20.77  -0.79 (-3.66%)

After market: 20.6999 -0.07 (-0.34%)

Fundamental Rating

3

SRPT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. SRPT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, SRPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year SRPT has reported negative net income.
In the past year SRPT has reported a negative cash flow from operations.
In the past 5 years SRPT reported 4 times negative net income.
In the past 5 years SRPT reported 4 times negative operating cash flow.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

With an excellent Return On Assets value of -7.17%, SRPT belongs to the best of the industry, outperforming 85.82% of the companies in the same industry.
The Return On Equity of SRPT (-21.74%) is better than 84.20% of its industry peers.
Industry RankSector Rank
ROA -7.17%
ROE -21.74%
ROIC N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

The Gross Margin of SRPT (81.82%) is better than 85.82% of its industry peers.
SRPT's Gross Margin has been stable in the last couple of years.
SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRPT has more shares outstanding
The number of shares outstanding for SRPT has been increased compared to 5 years ago.
The debt/assets ratio for SRPT has been reduced compared to a year ago.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

SRPT has an Altman-Z score of -0.19. This is a bad value and indicates that SRPT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SRPT (-0.19) is better than 61.94% of its industry peers.
SRPT has a Debt/Equity ratio of 1.00. This is a neutral value indicating SRPT is somewhat dependend on debt financing.
SRPT's Debt to Equity ratio of 1.00 is on the low side compared to the rest of the industry. SRPT is outperformed by 77.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Altman-Z -0.19
ROIC/WACCN/A
WACC6.31%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 4.02 indicates that SRPT has no problem at all paying its short term obligations.
SRPT has a Current ratio (4.02) which is comparable to the rest of the industry.
A Quick Ratio of 2.46 indicates that SRPT has no problem at all paying its short term obligations.
SRPT's Quick ratio of 2.46 is on the low side compared to the rest of the industry. SRPT is outperformed by 68.76% of its industry peers.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 2.46
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

6

3. Growth

3.1 Past

SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2545.45%.
SRPT shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.16%.
Measured over the past years, SRPT shows a very strong growth in Revenue. The Revenue has been growing by 37.94% on average per year.
EPS 1Y (TTM)-2545.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1343.24%
Revenue 1Y (TTM)59.16%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%80.15%

3.2 Future

Based on estimates for the next years, SRPT will show a very strong growth in Earnings Per Share. The EPS will grow by 32.54% on average per year.
Based on estimates for the next years, SRPT will show a quite strong growth in Revenue. The Revenue will grow by 11.47% on average per year.
EPS Next Y-185.11%
EPS Next 2Y69.97%
EPS Next 3Y59.85%
EPS Next 5Y32.54%
Revenue Next Year36.88%
Revenue Next 2Y24.39%
Revenue Next 3Y18.38%
Revenue Next 5Y11.47%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRPT. In the last year negative earnings were reported.
SRPT is valuated cheaply with a Price/Forward Earnings ratio of 3.15.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRPT indicates a rather cheap valuation: SRPT is cheaper than 98.56% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, SRPT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.15
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

SRPT's earnings are expected to grow with 59.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.97%
EPS Next 3Y59.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SRPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (6/18/2025, 8:00:00 PM)

After market: 20.6999 -0.07 (-0.34%)

20.77

-0.79 (-3.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners96.57%
Inst Owner Change-0.83%
Ins Owners4.4%
Ins Owner Change3.27%
Market Cap2.04B
Analysts83.13
Price Target95.2 (358.35%)
Short Float %9.86%
Short Ratio1.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-199.37%
Min EPS beat(2)-376.26%
Max EPS beat(2)-22.48%
EPS beat(4)2
Avg EPS beat(4)280.81%
Min EPS beat(4)-376.26%
Max EPS beat(4)1173.24%
EPS beat(8)6
Avg EPS beat(8)609.68%
EPS beat(12)7
Avg EPS beat(12)362.51%
EPS beat(16)9
Avg EPS beat(16)271.74%
Revenue beat(2)2
Avg Revenue beat(2)4.86%
Min Revenue beat(2)2.86%
Max Revenue beat(2)6.86%
Revenue beat(4)3
Avg Revenue beat(4)3.13%
Min Revenue beat(4)-9.09%
Max Revenue beat(4)11.9%
Revenue beat(8)6
Avg Revenue beat(8)4.15%
Revenue beat(12)9
Avg Revenue beat(12)3.16%
Revenue beat(16)11
Avg Revenue beat(16)2.72%
PT rev (1m)-36.96%
PT rev (3m)-48.12%
EPS NQ rev (1m)2.17%
EPS NQ rev (3m)-65.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-116.7%
Revenue NQ rev (1m)-2.65%
Revenue NQ rev (3m)-26.75%
Revenue NY rev (1m)-1.17%
Revenue NY rev (3m)-18.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.15
P/S 0.91
P/FCF N/A
P/OCF N/A
P/B 1.79
P/tB 1.83
EV/EBITDA N/A
EPS(TTM)-2.69
EYN/A
EPS(NY)6.59
Fwd EY31.71%
FCF(TTM)-7.1
FCFYN/A
OCF(TTM)-5.57
OCFYN/A
SpS22.72
BVpS11.63
TBVpS11.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.17%
ROE -21.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.82%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score2
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 386.06%
Cap/Sales 6.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.02
Quick Ratio 2.46
Altman-Z -0.19
F-Score2
WACC6.31%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2545.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1343.24%
EPS Next Y-185.11%
EPS Next 2Y69.97%
EPS Next 3Y59.85%
EPS Next 5Y32.54%
Revenue 1Y (TTM)59.16%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%80.15%
Revenue Next Year36.88%
Revenue Next 2Y24.39%
Revenue Next 3Y18.38%
Revenue Next 5Y11.47%
EBIT growth 1Y-23.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-136.36%
EBIT Next 3Y61.22%
EBIT Next 5Y48.47%
FCF growth 1Y-48.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.22%
OCF growth 3YN/A
OCF growth 5YN/A